MYD88 and Cognitive impairment: Targeting neuroinflammation with alogliptin, a dipeptidyl peptidase-4 inhibitor, has shown neuroprotective effects by targeting the TLR4/MYD88/NF-κB signaling cascade against lipopolysaccharide (LPS)-induced neuroinflammation and cognitive impairment in mice [27].